Oct. 26, 2018—NeoGenomics has entered into a definitive agreement to acquire Genoptix for $125 million in cash and 1 million shares of NeoGenomics common stock. “The acquisition of Genoptix enhances NeoGenomics’ leadership in the oncology test market, significantly expanding our coverage of oncology practices, increasing our customer reach, and leaving us better positioned for growth,” Douglas M. VanOort, NeoGenomics’ chairman ...
Read More »Home >> Tag Archives: Genoptix
Genoptix completes Rosetta acquisition
June 2018—Rosetta Genomics’ stockholders have approved the acquisition of the company by Genoptix, which will immediately begin marketing, selling, and distributing Rosetta Genomics’ products.
Read More »Genoptix to acquire Rosetta Genomics, 3/18
March 2018—Genoptix and Rosetta Genomics announced they have entered into a definitive merger agreement under which Genoptix will acquire all of the outstanding shares of Rosetta Genomics for a total gross purchase price of $10 million.
Read More »Genoptix, Bionano Genomics strategic alliance, 8/17
August 2017—Genoptix and Bionano Genomics announced an exclusive agreement to co-develop information-rich diagnostics for selected hematologic oncology indications in the United States using Bionano’s Saphyr system.
Read More »